文献速递先天性心脏病外科

镰状细胞病及镰状细胞特质患者先天性心脏病手术后的结局

Outcomes of Patients With Sickle Cell Disease and Trait After Congenital Heart Disease Surgery.
PubMed 文献 · Ann Thorac Surg · 2022-04-26

基于胸外科医师学会先天性心脏病手术数据库2014至2019年的回顾性研究,纳入镰状细胞病73例、镰状细胞特质411例及对照36501例,比较围术期结局。三组手术死亡率、手术时长、体外循环时间及主动脉阻断时间无显著差异;镰状细胞病组术后心脏骤停率高于倾向性评分匹配对照组(5.5% vs 0%,P < .05)。作者认为此类患者可接受心脏手术且未观察到死亡率增加。

要点

  • 镰状细胞病、镰状细胞特质与对照组的手术死亡率无显著差异。
  • 镰状细胞病组术后心脏骤停率高于匹配对照组(5.5% vs 0%,P < .05)。
  • 作者认为此类患者可接受心脏手术且未观察到死亡率增加。

核心结论

  • 镰状细胞病或镰状细胞特质患者接受心胸手术后手术死亡率与对照患者相似。
  • 此类患者可能需要独特的围术期管理,但可接受心脏手术且未观察到死亡率增加。

研究设计与样本

  • 回顾性综述,纳入胸外科医师学会先天性心脏病手术数据库中2014年至2019年有记录的镰状细胞病或镰状细胞特质患者。
  • 研究人群包括镰状细胞病组73例、镰状细胞特质组411例和对照组36501例。
  • 主要结局为手术死亡率,次要结局包括术后并发症。
  • 对镰状细胞病组和镰状细胞特质组分别与对照组进行一对一倾向性评分匹配后进一步分析。

主要发现

  • 手术时年龄中位数(25%至75%四分位距)在镰状细胞病组为2.8(0.4至9.7)岁,镰状细胞特质组为0.60(0.2至3.1)岁,对照组为0.70(0.2至6.4)岁。
  • 三组间手术死亡率、手术时长、体外循环时间和主动脉阻断时间无显著差异。
  • 镰状细胞病组术后心脏骤停率高于其倾向性评分匹配对照组(5.5% vs 0%,P < .05)。
  • 除术后心脏骤停外,镰状细胞病组和镰状细胞特质组分别与其匹配对照组之间的其他结局无统计学显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sickle cell disease (SCD) is a hemoglobinopathy that can cause multiorgan dysfunction. This study assessed the perioperative outcomes of patients undergoing operations for congenital heart disease who had SCD or sickle cell trait (SCT). METHODS: We performed a retrospective review of patients with SCD or SCT who had records in The Society of Thoracic Surgeons Congenital Heart Surgery Database between 2014 and 2019. The primary outcome was operative mortality. Secondary outcomes included postoperative complications. One-to-one propensity score matching was performed between the SCD and SCT groups and the control group for further analysis. RESULTS: Our study population consisted of 73, 411, and 36 501 patients in the SCD, SCT, and control groups, respectively. Median (25%-75% interquartile range) age at surgery was 2.8 (0.4-9.7), 0.60 (0.2-3.1), and 0.70 (0.2-6.4) years in the SCD, SCT, and control cohorts, respectively. Operative mortality, surgery duration, cardiopulmonary bypass time, and cross-clamp time were not significantly different among the 3 groups. The SCD group had a higher rate of postsurgical cardiac arrest than its propensity score-matched control group (5.5% vs 0%, P < .05); otherwise, there were no statistically significant differences in the outcomes between the SCD and SCT groups and their respective matched control groups. CONCLUSIONS: Operative mortality after cardiothoracic procedures in patients with SCD or SCT appeared similar to our control patients. While these patients may require unique perioperative management, they can undergo cardiac surgery without an observed increase in mortality.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Misra A, Halas R, Kobayashi D, et al. Outcomes of Patients With Sickle Cell Disease and Trait After Congenital Heart Disease Surgery. Ann Thorac Surg. 2022. PMID: 35483424. doi:10.1016/j.athoracsur.2022.04.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。